Plasma inhibitory activity against tumour necrosis factor in fulminant hepatic failure

Clinical Science

Volumn 90, Issue 1, 1996, Pages 77-80

  Keane, Helen M ^a   Sheron, Nick ^a   Goka, John ^a   Hughes, Robin D ^a   Williams, Roger ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cytokine; Fulminant hepatic failure; Tumour necrosis factor soluble receptor; Tumour necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HUMAN; LIVER FAILURE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0030048268     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0900077     Document Type: Article

References (31)

1. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science (Washington DC) 1986; 234: 470-4.
2. Tracey KJ, Lowry SF, Fahey TJ III, et al. Cachectin/TNF induces lethal shock and stress hormone responses in the dog, Surg Gynecol Obstet 1987; 164: 415-22.
3. Maury CP, Teppo AM. Circulating TNF alpha (cachectin) in myocardial infarction. J Intern Med 1989; 255: 333-6.
4. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of TNF in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
5. Kern P, Hemmer CJ, Van Damme J, Gruss HJ, Dietrich M. Elevated TNF-alpha and IL-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 1989; 87: 139-43.
6. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams R. Increased plasma TNF in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917-20.
7. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced TNF and IL-1 in fulminant hepatic failure. Lancet 1988; ii: 72-4.
8. Sheron N, Goka J, Wendon J, et al. Highly elevated plasma cytokines in fulminant hepatic failure: correlations with multiorgan failure and death. Hepatology 1990; 12: 939.
9. Schall TJ, Lewis M, Koller KJ, et al. Molecular cloning and expression of a receptor for human tumour necrosis factor. Cell 1990; 61: 361-5.
10. Englemann H, Novick D, Wallach D. Two tumour necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumour necrosis factor receptors. J Biol Chem 1990; 265: 1531-6.
11. Gatanga T, Hwang CD, Kohr W, et al. Purification and characterisation of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990; 87: 8781-4.
12. Nophar Y, Kemper O, Brakebusch C, et al. Soluble forms of tumour necrosis factor soluble receptors (TNF-Rs), The cDNA for the type I TNF-R cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990; 9: 3269-78.
13. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumour necrosis factor receptor p55. Blood 1994; 83: 113-18.
14. Shapiro L, Clark BD, Orencole SF, Poutsiaka DD, Granowitz EV, Dinarello CA. Detection of tumour necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 1993; 167: 1344-50.
15. Lantz M, Bjornberg F, Olsson I, Richter J. Adherence of neutrophils induces release of soluble tumour necrosis factor receptor forms. J Immunol 1994; 152: 1362-9.
16. Latini R, Bianchi M, Correale E, et al. Cytokines in acute myocardial infarction: selective increase in circulating tumour necrosis factor, its soluble receptor and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 1994; 23: 1-6.
17. Kern WV, Engel A, Schieffer S, Prummer O, Kern P. Circulating tumour necrosis factor alpha (TNF), soluble TNF receptors and interleukin-6 in human subacute bacterial endocarditis. Infect Immun 1993; 61: 5413-16.
18. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845-9.
19. Van der Poll T, Jansen J, Van Leenen D, et al. Release of soluble receptors for tumour necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993; 168: 955-60.
20. Tilg H, Vogel W, Wiedermann CJ, et al. Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease. Hepatology 1993; 18: 1132-8.
21. Andus T, Gross V, Holstege A, et al. High concentrations of soluble tumor necrosis factor receptors in ascites. Hepatology 1992; 16: 749-55.
22. Aderka D, Wysenbeek A, Englemann H, et al. Correlation between serum levels of soluble tumour necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1111-20.
23. Lesslauer W, Tabuchi H, Gentz R, et al. Recombinant soluble tumour necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991; 21: 2883-6.
24. Ulich TR, Yin S, Remick DG, Russell D, Eisenberg SP, Kohno T. Intratracheal administration of endotoxin and cytokines. The soluble tumor necrosis factor receptor type I inhibits acute inflammation. Am J Pathol 1993; 142: 1335-8.
25. Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumour necrosis factor. Production, purification and characterisation. J Biol Chem 1985; 260: 2345-4.
26. 2-macroglobulins. Lab Invest 1991; 65: 3-14.
27. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J Clin Invest 1992; 90: 533-6.
28. Ertel W, Scholl FA, Gallati H, Bonaccio M, Schildberg F-W, Trentz O. Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis. Arch Surg 1994; 129: 1330-7.
29. Granowitz EV, Santos A, Poutsiaka DD, et al. Production of interleukin-1 receptor antagonist during experimental endotoxemia. Lancet 1991; 338: 1423-4.
30. Hughes RD, Cochrane AMG, Thomson AD, Murray-Lyon IM, Williams R. The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. Br J Exp Pathol 1976; 57: 348-53.
31. Hughes RD, Nagaki M, Keane H, Sheron N, Williams R. Artificial liver support in acute liver failure: A review of studies at King's. Artif Organs 1992; 16: 167-70.